Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | Q9HBH1 | 1/20 | 0.34 | |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | TPMT | P51580 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.32 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5156582 | 0.82 | CHRNA4 (0.50) | CHRNA4SMN1; SMN2MAPTALDH1A1HPGD | |
| SCHEMBL6857897 | 0.82 | CHRNA4 (0.50) | CHRNA4SMN1; SMN2MAPTALDH1A1CYP3A4 | |
| SCHEMBL6856079 | 0.78 | CHRNA4 (0.47) | CHRNA4SMN1; SMN2MAPTALDH1A1HPGD | |
| SCHEMBL7072378 | 0.71 | CHRNA4 (0.49) | CHRNA4SMN1; SMN2ALDH1A1HPGDCYP3A4 | |
| SCHEMBL10888814 | 0.67 | CA12 (0.47) | CHRNA4SMN1; SMN2MAPTHPGDTPMT | |
| SCHEMBL8579431 | 0.66 | ACHE (0.37) | CHRNA4MAPTALDH1A1HPGDCYP3A4 | |
| SCHEMBL28157666 | 0.66 | ACHE (0.42) | CHRNA4SMN1; SMN2MAPTALDH1A1HPGD | |
| SCHEMBL219096 | 0.65 | TUBB4A (0.55) | MAPTALDH1A1HPGDCYP3A4TPMT | |
| SCHEMBL28275397 | 0.65 | TUBB4A (0.55) | MAPTALDH1A1HPGDCYP3A4TPMT | |
| SCHEMBL7075588 | 0.64 | MAPT (0.35) | MAPTALDH1A1HPGDCYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541406-B2 | Thiadiazole derivatives for the treatment of neurodegenerative diseases | NV REMYND (BE) | 2013-09-24 | — | — | US | disclosed |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2010-10-14 | — | — | US | disclosed |
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-09-17 | — | — | US | disclosed |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | NV REMYND (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233911-A2 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CHRNA4 1920/4885SMN1; SMN2 4/4885PDF 246/4885 |
| US-20100261707-A9 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CHRNA4 1920/4885SMN1; SMN2 4/4885PDF 246/4885 |
| US-20090054410-A1 | THIADIAZOLE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | CHRNA4 1920/4885SMN1; SMN2 4/4885PDF 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.